4Vote!
VitaBeat (Free subscription) | 07/23/2008
... is very likely to have an important role n the management of prostate cancer patients," said Dr. Howard Sandler, a radiation oncologist. Dr. Robert Reiter, a urologist at UCLA's Jonsson Comprehensive Cancer Center, told the Los Angeles Times, "It's pretty safe to say that we are going to have a lot more to offer patients when this drug gets approved."Cougar Biotechnology of Los Angeles...
2Vote!
Seattle Times (Free subscription) | 07/23/2008
"There is a general sense in the prostate-cancer community that this agent is extremely promising and is very likely to have an important role in the management of prostate-cancer patients," said Dr. Howard Sandler, a radiation oncologist at the University of Michigan who is a spokesman for the American Society of Clinical Oncology.
2Vote!
Houston Chronicle (Free subscription) | 07/23/2008
... is very likely to have an important role in the management of prostate cancer patients," said Dr. Howard Sandler, a radiation oncologist at the University of Michigan.Experts expect the new drug, called abiraterone, to be widely available by 2011. It could find use among most of the 28,000 U.S. men diagnosed each year with the most aggressive, and almost always fatal, type of prostate...
1Vote!
Denver Post (Free subscription) | 07/23/2008
... is very likely to have an important role in the management of prostate-cancer patients," said Dr. Howard Sandler, a radiation oncologist at the University of Michigan who is a spokesman for the American Society of Clinical Oncology. "It's pretty safe to say that we are going to have a lot more to offer patients when this drug gets approved," added Dr. Robert Reiter, a urologist at...
